Acrivon Therapeutics’ (ACRV) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a research report released on Thursday, MarketBeat Ratings reports. HC Wainwright currently has a $22.00 price objective on the stock.

Several other research firms have also recently weighed in on ACRV. BMO Capital Markets restated an “outperform” rating and issued a $28.00 price target (up previously from $25.00) on shares of Acrivon Therapeutics in a research note on Monday, September 16th. LADENBURG THALM/SH SH raised Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Monday, September 16th. Piper Sandler Companies reaffirmed a “buy” rating and set a $30.00 price target on shares of Acrivon Therapeutics in a report on Friday, September 6th. Finally, JMP Securities reissued a “market outperform” rating and set a $17.00 price objective on shares of Acrivon Therapeutics in a report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $23.67.

Acrivon Therapeutics Stock Down 12.1 %

Shares of ACRV opened at $6.96 on Thursday. The company has a market capitalization of $216.73 million, a P/E ratio of -2.58 and a beta of 0.66. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $11.90. The firm has a 50 day moving average of $7.78 and a 200 day moving average of $7.77.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of large investors have recently made changes to their positions in ACRV. American International Group Inc. lifted its stake in shares of Acrivon Therapeutics by 39.2% in the 1st quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after purchasing an additional 1,695 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Acrivon Therapeutics during the second quarter valued at approximately $58,000. XTX Topco Ltd bought a new position in Acrivon Therapeutics in the second quarter worth approximately $61,000. Rhumbline Advisers boosted its stake in shares of Acrivon Therapeutics by 48.9% during the 2nd quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock worth $94,000 after acquiring an additional 5,320 shares during the last quarter. Finally, Barclays PLC grew its position in shares of Acrivon Therapeutics by 51.2% during the 3rd quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the period. 71.62% of the stock is currently owned by institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.